CRISPR Therapeutics Leverages $2 Billion Cash Reserve to Scale Gene-Editing Pipeline

CRISPR Therapeutics (CRSP) is navigating a transition from a research-heavy biotech to a commercial-stage entity, supported by a cash reserve of nearly $2 billion as of the end of 2025. This liquidity cushion allows the company to sustain operations while scaling its first approved product. While the company reported a net loss of $578.6 million last year, the commercial trajectory of its gene-editing therapy, Casgevy, shows signs of acceleration. Priced at $2.2 million per treatment for sickle cell disease and transfusion-dependent beta thalassemia, Casgevy generated $116 million in total sales for 2025, with $54 million of that revenue occurring in the fourth quarter alone. Beyond its initial success, the company is advancing five additional therapies in clinical trials to target larger patient populations. Most notable are CXT310 and CXT320, 'in vivo' treatments designed to edit genes directly in the body to lower blood lipids and reduce cardiovascular risk. Additionally, the company is developing CTX112 (zugo-cel), a next-generation 'off-the-shelf' CAR T-cell therapy. This candidate is currently being tested for autoimmune disorders such as lupus and systemic sclerosis, as well as B-cell cancers, which represent the most common blood cancers in the United States. Investors are currently weighing the company's substantial annual losses against its ability to provide functional cures. The current cash position provides the necessary breathing room to move these high-potential therapies through the regulatory approval process.